阿尔茨海默病的胆碱能药物治疗  

Cholinergic therapeutics for Alzheimer's disease

作　　者：陈子晟[1] 罗焕敏[1] 

机构地区：[1]暨南大学医学院药理教研室,广州510632

出　　处：《中国新药杂志》2001年第6期415-419,共5页Chinese Journal of New Drugs

摘　　要：阿尔茨海默病是一种中枢神经系统进行性退变疾病 ,其病因仍未确定 ,但胆碱能神经系统受损是公认的原因之一。本文将治疗阿尔茨海默病的胆碱能药物分为 4类 :①作用于突触前的乙酰胆碱前体。②作用于突触间隙的乙酰胆碱酯酶抑制剂。③作用于突触后的M1受体激动剂。④促进乙酰胆碱释放的药物 ,对其作用机制、临床应用及新进展作一综述。Alzheimer's disease (AD) is a progressive neurodegenerative disorder with severe cognitive, behavioral,and functional impairment.Although its etiology is still unknown,it is generally accepted as related to the cholinergic deficit in the brain. In this paper,the cholinergic therapeutics for AD including the precursors of acetylcholine, the acetylcholinesterase inhibitor, the postsynaptic muscarinic M 1 receptor agonists,and agents facilitating acetylcholine release were reviewed.

关 键 词：阿尔茨海默病 乙酰胆碱 乙酰胆碱酯酶抑制剂 

分 类 号：R971.91[医药卫生—药品] R749.16[医药卫生—药学]